Advances in the development of targeted therapies for renal cell carcinoma

Welireg Wins FDA Approval for Advanced Renal Cell Carcinoma, the Second for the Merck DrugПодробнее

Immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: ASCO GU 2023Подробнее

The Clinical Advantages of Combination Therapies in Advanced RCCПодробнее

Renal cell carcinomaПодробнее

Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic LandscapeПодробнее

Renal Cancer IVC Involvement Metastatic RCC Cytoreductive Nephrectomy Targeted Therapy ImmunotherapyПодробнее

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

Stanford Cancer Institute Breakthroughs in Cancer: Luis Diaz, MDПодробнее

212 Drugs in development for RAI-refractory differentiated thyroid cancer. New Molecular TargetsПодробнее

Integration of Surgery and Systemic Therapy for Advanced Renal Cell Carcinoma in the Targeted The...Подробнее

New and Emerging Systemic Treatment Options for Metastatic Kidney Cancer Scott S. Tykodi, M.D., PhD.Подробнее

Immunotherapy and targeted therapy for advanced aRCCПодробнее

Surgical Management of Locally Advanced Renal Cell Carcinoma - Christopher Wood, M.D.Подробнее

Guidelines Based Management of Localized and Locally Advanced RCCПодробнее

Management of Locally Advanced Kidney Cancer Christopher G. Wood, MDПодробнее

Renal Cell Carcinoma: Past, Present, and FutureПодробнее

Case-Based Tumor Board: Confronting Management Controversies in Renal Cell CarcinomaПодробнее

Novel therapy for Lung Cancer: From targeted therapy to immuno-therapy and back again!Подробнее

Dr. Wainberg discusses Advances in Chemotherapy for Pancreatic CancerПодробнее